
Verrica Pharmaceuticals Inc
NASDAQ:VRCA

Income Statement
Earnings Waterfall
Verrica Pharmaceuticals Inc
Revenue
|
7.6m
USD
|
Cost of Revenue
|
-2.7m
USD
|
Gross Profit
|
4.8m
USD
|
Operating Expenses
|
-70.7m
USD
|
Operating Income
|
-65.8m
USD
|
Other Expenses
|
-10.7m
USD
|
Net Income
|
-76.6m
USD
|
Income Statement
Verrica Pharmaceuticals Inc
Dec-2017 | Mar-2018 | Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||||||||||||||||||||
Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
12
N/A
|
12
N/A
|
12
N/A
|
12
N/A
|
0
-96%
|
1
+49%
|
9
+1 300%
|
9
+1%
|
9
-4%
|
9
0%
|
3
-63%
|
5
+60%
|
9
+74%
|
14
+56%
|
9
-34%
|
8
-18%
|
|
Gross Profit | ||||||||||||||||||||||||||||||
Cost of Revenue |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(2)
|
(2)
|
(2)
|
(3)
|
|
Gross Profit |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
8
N/A
|
(1)
N/A
|
(1)
+7%
|
2
N/A
|
4
+118%
|
7
+62%
|
12
+65%
|
7
-42%
|
5
-29%
|
|
Operating Income | ||||||||||||||||||||||||||||||
Operating Expenses |
(4)
|
(6)
|
(10)
|
(15)
|
(22)
|
(26)
|
(29)
|
(29)
|
(30)
|
(32)
|
(33)
|
(36)
|
(40)
|
(42)
|
(44)
|
(46)
|
(43)
|
(39)
|
(37)
|
(33)
|
(30)
|
(30)
|
(33)
|
(51)
|
(68)
|
(84)
|
(93)
|
(84)
|
(71)
|
|
Selling, General & Administrative |
(1)
|
(2)
|
(3)
|
(6)
|
(9)
|
(10)
|
(12)
|
(13)
|
(15)
|
(16)
|
(18)
|
(19)
|
(25)
|
(26)
|
(28)
|
(32)
|
(27)
|
(26)
|
(23)
|
(19)
|
(17)
|
(17)
|
(17)
|
(34)
|
(47)
|
(59)
|
(70)
|
(66)
|
(59)
|
|
Research & Development |
(4)
|
(4)
|
(7)
|
(9)
|
(13)
|
(16)
|
(17)
|
(16)
|
(15)
|
(16)
|
(15)
|
(17)
|
(16)
|
(16)
|
(16)
|
(15)
|
(16)
|
(13)
|
(14)
|
(13)
|
(12)
|
(12)
|
(14)
|
(17)
|
(20)
|
(23)
|
(20)
|
(16)
|
(12)
|
|
Other Operating Expenses |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(3)
|
(3)
|
(3)
|
0
|
|
Operating Income |
(4)
N/A
|
(6)
-30%
|
(10)
-75%
|
(15)
-49%
|
(22)
-45%
|
(26)
-21%
|
(29)
-8%
|
(29)
-1%
|
(30)
-5%
|
(32)
-6%
|
(33)
-3%
|
(36)
-9%
|
(40)
-11%
|
(30)
+25%
|
(32)
-7%
|
(34)
-7%
|
(31)
+10%
|
(38)
-24%
|
(37)
+4%
|
(24)
+36%
|
(21)
+10%
|
(22)
-5%
|
(25)
-11%
|
(49)
-96%
|
(63)
-29%
|
(77)
-22%
|
(81)
-5%
|
(78)
+4%
|
(66)
+15%
|
|
Pre-Tax Income | ||||||||||||||||||||||||||||||
Interest Income Expense |
0
|
0
|
0
|
1
|
1
|
2
|
2
|
2
|
2
|
1
|
0
|
(1)
|
(3)
|
(4)
|
(4)
|
(4)
|
(4)
|
(4)
|
(4)
|
(3)
|
(2)
|
(0)
|
1
|
1
|
(1)
|
(3)
|
(6)
|
(7)
|
(11)
|
|
Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(1)
|
(1)
|
0
|
0
|
0
|
(3)
|
0
|
0
|
0
|
(0)
|
|
Total Other Income |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
(0)
|
|
Pre-Tax Income |
(4)
N/A
|
(6)
-29%
|
(10)
-73%
|
(15)
-46%
|
(21)
-42%
|
(25)
-20%
|
(26)
-7%
|
(27)
-1%
|
(28)
-6%
|
(31)
-8%
|
(33)
-8%
|
(37)
-13%
|
(43)
-14%
|
(34)
+21%
|
(36)
-7%
|
(39)
-6%
|
(35)
+9%
|
(43)
-21%
|
(41)
+4%
|
(28)
+31%
|
(24)
+13%
|
(23)
+8%
|
(23)
-4%
|
(48)
-106%
|
(67)
-39%
|
(81)
-21%
|
(87)
-8%
|
(85)
+2%
|
(77)
+10%
|
|
Net Income | ||||||||||||||||||||||||||||||
Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Income from Continuing Operations |
(4)
|
(6)
|
(10)
|
(15)
|
(21)
|
(25)
|
(26)
|
(27)
|
(28)
|
(31)
|
(33)
|
(37)
|
(43)
|
(34)
|
(36)
|
(39)
|
(35)
|
(43)
|
(41)
|
(28)
|
(24)
|
(23)
|
(23)
|
(48)
|
(67)
|
(81)
|
(87)
|
(85)
|
(77)
|
|
Net Income (Common) |
(4)
N/A
|
(6)
-29%
|
(10)
-73%
|
(15)
-46%
|
(21)
-42%
|
(25)
-20%
|
(26)
-7%
|
(27)
-1%
|
(28)
-6%
|
(31)
-8%
|
(33)
-8%
|
(37)
-13%
|
(43)
-14%
|
(34)
+21%
|
(36)
-7%
|
(39)
-6%
|
(35)
+9%
|
(43)
-21%
|
(41)
+4%
|
(28)
+31%
|
(24)
+13%
|
(23)
+8%
|
(23)
-4%
|
(48)
-106%
|
(67)
-39%
|
(81)
-21%
|
(87)
-8%
|
(85)
+2%
|
(77)
+10%
|
|
EPS (Diluted) |
-0.18
N/A
|
-0.23
-28%
|
-0.87
-278%
|
-0.58
+33%
|
-0.8
-38%
|
-0.99
-24%
|
-1.05
-6%
|
-1.07
-2%
|
-1.13
-6%
|
-1.22
-8%
|
-1.32
-8%
|
-1.5
-14%
|
-1.71
-14%
|
-1.32
+23%
|
-1.31
+1%
|
-1.4
-7%
|
-1.3
+7%
|
-1.56
-20%
|
-1.5
+4%
|
-0.62
+59%
|
-0.72
-16%
|
-0.52
+28%
|
-0.53
-2%
|
-1.04
-96%
|
-1.48
-42%
|
-1.75
-18%
|
-1.88
-7%
|
-1.83
+3%
|
-1.48
+19%
|